Comparison of maternal and fetal complications in women with various phenotypes of polycystic ovary syndrome

Document Type : Original Article


1 Phd student of Research, Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Assistant professor of Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Senior Researcher, Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Assistant professor, School of Nursing and Midwifery, Varamin Branch, Islamic Azad University, Tehran, Iran.

5 Professor, Department of Reproductive Endocrinology, Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

6 Professor, Department of Endocrinology, Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Introduction: The prevalence of maternal and fetal complications in pregnant women with polycystic ovary syndrome (PCOS) is higher than non-infected women. This study was performed with aim to evaluate the prevalence of pregnancy complications in women with different phenotypes of polycystic ovary syndrome based on the NIH in addition to Rotterdam criteria.
 Methods: In this retrospective study, the pregnancy records of 266 PCOS women were investigated based on their medical file in 2014-2016. These women based on PCOS related clinical symptoms were divided to two groups: The first group, or group A (severe phenotype), included women who had all three clinical signs of oligo-anovulation, hyper-androgenism, and ovarian cysts, or only two signs of oligo-ovulation and hyper-androgenism when the disease was diagnosed. Group B included people who had only hyper-androgenism with ovarian cysts (PCOM) or oligovulation with ovarian cysts (mild phenotype).The maternal and fetal complications during pregnancy was retrospectively evaluated between two groups based on the participants’ medical records information. Data were analyzed by SPSS software (version 17) and Mann-Whitney, Chi-square, T test and Logistic Regression. P<0.05 was considered statistically significant.
Results: Among maternal and fetal complications, low birth weight was significantly different between the two groups. After adjusting with age, body mass index and number of pregnancies, the odds ratio of low birth weight baby in group A compared to group B was 2.6 (95% CI; 1.5-2.9, p <0.01). The study found no statistically significant difference in gestational diabetes, preterm delivery, or the chance of spontaneous abortion between different PCOS phenotypes.
Conclusion: The chance of LBW in women with sever form of PCOS (group A) is higher than women with moderate form of the disease (group B). In clinical practice, it is recommended that the PCOS phenotype should be considered as an affecting factor on fetal outcomes in pregnancy.


  1. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2006; 20(2):193-205.
  2. Azziz R,Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89(6):2745-9.
  3. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83(9):3078-82.
  4. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 2011; 9:39.
  5. Hsu MI. Clinical characteristics in Taiwanese women with polycystic ovary syndrome. Clin Exp Reprod Med 2015; 42(3):86-93.
  6. Zawadski JK, Dunaif A. (1992) Diagnostic Criteria for Polycystic Ovary Syndrome: Towards a Rational Approach. In: Dunaif A, Givens JR, Haseltine F, Eds. Polycystic Ovary Syndrome, Blackwell Scientific, Boston; 1992. p. 377-384.
  7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81(1):19-25
  8. Farzaneh F. The Effect of Clomiphene Citrate Versus Letrozole on Pregnancy Rate in Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial. Crescent Journal of Medical and Biological Sciences 2019; 6(3):335-340.
  9. Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med 2008; 26(1):72-84.
  10. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 2013; 11:56.
  11. Palomba S, Falbo A, Russo T, Tolino A, Orio F, Zullo F. Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil Steril 2010; 94(5):1805-11.
  12. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007; 88(5):1389-95.
  13. Mumm H, Jensen DM, Sørensen JA, Andersen LL, Ravn P, Andersen M, et al. Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes. Acta Obstet Gynecol Scand 2015; 94(2):204-11.
  14. Kollmann M, Klaritsch P, Martins WP, Guenther F, Schneider V, Herzog SA, et al. Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions. Hum Reprod 2015; 30(10):2396-403.
  15. Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol 2014; 12:89.
  16. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. american association of clinical endocrinologists, american college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 1. Endocr Pract 2015; 21(11):1291-300.
  17. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:1440-7.
  18. Bener A, Saleh NM, Al-Hamaq A. Prevalence of gestational diabetes and associated maternal and neonatal complications in a fast-developing community: global comparisons. Int J Womens Health 2011; 3:367-73.
  19. Burgers JA, Fong SL, Louwers YV, Valkenburg O, de Jong FH, Fauser BC, et al. Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference? J Clin Endocrinol Metab 2010; 95(12):E485-9
  20. Sir-Petermann T, Hitchsfeld C, Maliqueo M, Codner E, Echiburú B, Gazitúa R, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod 2005; 20(8):2122-6.
  21. Yamamoto M, Feigenbaum SL, Crites Y, Escobar, GJ, Yang J, Ferrara A, et al. Risk of preterm delivery in non-diabetic women with polycystic ovarian syndrome. J Perinatol 2012; 32(10):770-6.
  22. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001; 16(2):226-9.
  23. Ford HB, Schust DJ. Recurrent Pregnancy Loss: Etiology, Diagnosis, and Therapy. Rev Obstet Gynecol 2009; 2(2):76-83.
  24. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001; 16(12):2606-9.
  25. Liu L, Tong X, Jiang L, Li TC, Zhou F, Zhang S. A comparison of the miscarriage rate between women with and without polycystic ovarian syndrome undergoing IVF treatment. Eur J Obstet Gynecol Reprod Biol 2014; 176:178-82.
  26. Wang J, Wei Y, Diao F, Cui Y, Mao Y, Wang W, et al. The association between polycystic ovary syndrome and ectopic pregnancy after in vitro fertilization and embryo transfer. Am J Obstet Gynecol 2012; 209(2):139.e1-9.
  27. Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 1998; 69(4):682-90.
  28. Essah PA, Cheang KI, Nestler JE. The Pathophysiology of Miscarriage in Women with Polycystic Ovary Syndrome.Review and Proposed Hypothesis of Mechanisms Involved. Hormones (Athens) 2004; 3(4):221-7.
  29. Nojomi M, Akbarian A, Ashory-Moghadam S. Burden of abortion : induced and spontaneous. Arch Iranian Med 2006; 9(1):39-45.
  30. Behnoud N, Rezaei R, Esform E, Farzaneh F. The Relationship Between Endometrial Thickness and Endometrial Pattern With Pregnancy Rate Based on Positive Serum Beta-Human Chorionic Gonadotropin. International Journal of Womens Health and Reproduction Sciences 2019; 7(3):400-403.
  31. de la Rochebrochard E, Thonneau P. Paternal age and maternal age are risk factors for miscarriage; results of a multicentre European study. Hum Reprod 2002; 17(6):1649-56.
  32. Shennan AH, Bewley S. Why should preterm births be rising? BMJ 2006; 332(7547):924-5.
  33. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resstance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38(9):1165-74.
  34. Seli E, Duleba AJ. Should patients with polycystic ovarian syndrome be treated with metformin? Hum Reprod 2002; 17(9):2230-6.
  35. Hahn KA, Hatch EE, Rothman KJ, Mikkelsen EM, Brogly SB, Sørensen HT, et al. Body size and risk of spontaneous abortion among danish pregnancy planners. Paediatric and perinatal epidemiology 2014; 28(5):412-423.
  36. Helgstrand S, Andersen AM. Maternal underweight and the risk of spontaneous abortion. Acta Obstet Gynecol Scand 2005; 84(12):1197-201.
  37. Kwong WY, Wild AE, Roberts P, Willis AC, Fleming TP. Maternal undernutrition during the preimplantation period of rat development causes blastocyst abnormalities and programming of postnatal hypertension. Development 2000; 127(19):4195-202.
  38. Abecia JA, Forcada F, Lozano JM. A preliminary report on the effect of dietary energy on prostaglandin F2 alpha production in vitro, interferon-tau synthesis by the conceptus, endometrial progesterone concentration on days 9 and 15 of pregnancy and associated rates of embryo wastage in ewes. Theriogenology 1999; 52(7):1203-13.